Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association.
暂无分享,去创建一个
D. Pennell | A. Arai | B. Bozkurt | J. Udelson | T. M. Hoffman | R. Galanello | A. Piga | S. Lerakis | J. Wood | A. Cohen | M. Kiernan | J. Porter | J. M. Walker | A. Cohen
[1] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[2] L. Hou,et al. Endocrine complications in patients with thalassaemia major , 2013, International Journal of Pediatric Endocrinology.
[3] D. Pennell,et al. International survey of T2* cardiovascular magnetic resonance in β-thalassemia major , 2013, Haematologica.
[4] A. Piga,et al. Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial. , 2013, The American journal of medicine.
[5] N. Chattipakorn,et al. Ferric iron uptake into cardiomyocytes of β-thalassemic mice is not through calcium channels , 2013, Drug and chemical toxicology.
[6] E. Neufeld,et al. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone , 2013, Journal of Cardiovascular Magnetic Resonance.
[7] D. Pennell,et al. On myocardial siderosis and left ventricular dysfunction in hemochromatosis , 2013, Journal of Cardiovascular Magnetic Resonance.
[8] M. Lombardi,et al. Comparison of biventricular dimensions and function between pediatric sickle‐cell disease and thalassemia major patients without cardiac iron , 2013, American journal of hematology.
[9] T. Coates,et al. Exercise performance in thalassemia major: Correlation with cardiac iron burden , 2013, American journal of hematology.
[10] E. Vichinsky,et al. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. , 2013, Blood cells, molecules & diseases.
[11] I. Papassotiriou,et al. Correlation of NT-proBNP levels and cardiac iron concentration in patients with transfusion-dependent thalassemia major. , 2013, Blood cells, molecules & diseases.
[12] K. Anstrom,et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. , 2012, The New England journal of medicine.
[13] D. Pennell,et al. A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with β-Thalassemia Major and Iron Overload (CORDELIA). , 2012 .
[14] R. Galanello,et al. Renal aspects of thalassaemia a changing paradigm , 2012, European journal of haematology.
[15] S. Saad,et al. Left and right ventricular function and volume assessment in young thalassemia major patients with no related myocardial iron overload , 2012, Annals of Hematology.
[16] V. Positano,et al. Feasibility, reproducibility, and reliability for the T*2 iron evaluation at 3 T in comparison with 1.5 T , 2012, Magnetic resonance in medicine.
[17] P. Cianciulli,et al. Long‐term use of deferiprone significantly enhances left‐ventricular ejection function in thalassemia major patients , 2012, American journal of hematology.
[18] G. Felker,et al. Diuretics and ultrafiltration in acute decompensated heart failure. , 2012, Journal of the American College of Cardiology.
[19] D. Pennell,et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major , 2012, Haematologica.
[20] E. Terpos,et al. Sickle‐cell disease and the heart: review of the current literature , 2012, British journal of haematology.
[21] N. Chattipakorn,et al. T‐type calcium channel blockade improves survival and cardiovascular function in thalassemic mice , 2012, European journal of haematology.
[22] M. Cappellini,et al. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. , 2012, Blood reviews.
[23] E. Neufeld,et al. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. , 2012, Blood.
[24] J. Detterich,et al. Electrocardiographic consequences of cardiac iron overload in thalassemia major , 2012, American journal of hematology.
[25] T. Leung,et al. Thalassaemia in pregnancy. , 2012, Best practice & research. Clinical obstetrics & gynaecology.
[26] D. Pennell,et al. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major , 2012, Journal of Cardiovascular Magnetic Resonance.
[27] R. Galanello,et al. Deferasirox: pharmacokinetics and clinical experience , 2012, Expert opinion on drug metabolism & toxicology.
[28] L. A. Bonet,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.
[29] L. A. Bonet,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[30] Filippo Cademartiri,et al. Left and right ventricle assessment with Cardiac CT: validation study vs. Cardiac MR , 2012, European Radiology.
[31] D. Farmakis,et al. Contemporary Reviews in Cardiovascular Medicine Iron Overload Cardiomyopathy in Clinical Practice , 2011 .
[32] S. Heximer,et al. Iron Overload Decreases CaV1.3-Dependent L-Type Ca2+ Currents Leading to Bradycardia, Altered Electrical Conduction, and Atrial Fibrillation , 2011, Circulation. Arrhythmia and electrophysiology.
[33] J. Kwiatkowski. Management of transfusional iron overload – differential properties and efficacy of iron chelating agents , 2011, Journal of blood medicine.
[34] Z. Cabantchik,et al. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure , 2011, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[35] W. Au,et al. A synopsis of current care of thalassaemia major patients in Hong Kong. , 2011, Hong Kong medical journal = Xianggang yi xue za zhi.
[36] D. Pennell,et al. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload , 2011, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[37] A. Kattamis,et al. Impact of magnetic resonance imaging on cardiac mortality in thalassemia major , 2011, Journal of magnetic resonance imaging : JMRI.
[38] T. Coates,et al. Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial , 2011, Haematologica.
[39] Ioanna Tzoumari,et al. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. , 2011, Blood cells, molecules & diseases.
[40] T. Coates,et al. Quantitative computed tomography assessment of transfusional iron overload , 2011, British journal of haematology.
[41] S. Ha,et al. Intermediate-Term Evaluation Of A Pratical Chelation Protocol Based On Stratification Of Thalassemic Patients By Serum Ferritin And Magnetic Resonance Imaging Cardiac T2* , 2011, Hemoglobin.
[42] E. Vichinsky,et al. Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease , 2011, British journal of haematology.
[43] B. Gerber,et al. Iron overload in polytransfused patients without heart failure is associated with subclinical alterations of systolic left ventricular function using cardiovascular magnetic resonance tagging , 2011, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[44] Dudley J Pennell,et al. On T2* Magnetic Resonance and Cardiac Iron , 2011, Circulation.
[45] J. Neglia,et al. Reversible Fanconi syndrome in a pediatric patient on deferasirox , 2011, Pediatric blood & cancer.
[46] A. Kattamis,et al. Survival in a large cohort of Greek patients with transfusion‐dependent beta thalassaemia and mortality ratios compared to the general population , 2011, European journal of haematology.
[47] V. Positano,et al. Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* magnetic resonance imaging study , 2011, Haematologica.
[48] E. Neufeld,et al. Renal dysfunction in patients with thalassaemia , 2011, British journal of haematology.
[49] Vincenzo Russo,et al. Dispersion of repolarization and beta‐thalassemia major: the prognostic role of QT and JT dispersion for identifying the high‐risk patients for sudden death , 2011, European journal of haematology.
[50] Juerg Schwitter,et al. Training and accreditation in cardiovascular magnetic resonance in Europe: a position statement of the working group on cardiovascular magnetic resonance of the European Society of Cardiology. , 2011, European heart journal.
[51] Dudley J Pennell,et al. Value of black blood T2* cardiovascular magnetic resonance , 2011, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[52] B. Maisch,et al. Diabetic cardiomyopathy: fact or fiction? , 2001, Heart.
[53] A. Tsapas,et al. Is Deferasirox Implicated in Multiple Organ Failure in a Patient With Homozygous β-Thalassemia? , 2011, Angiology.
[54] T. Coates,et al. Revisiting the relationship between vitamin D deficiency, cardiac iron and cardiac function in thalassemia major , 2011, European journal of haematology.
[55] J. Wood,et al. Interdependence of cardiac iron and calcium in a murine model of iron overload. , 2011, Translational research : the journal of laboratory and clinical medicine.
[56] N. Sanfilippo,et al. Detection of Early Cardiac Dysfunction in Patients with Beta Thalassemia by Tissue Doppler Echocardiography , 2011, Echocardiography.
[57] D. Pennell,et al. Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance , 2011, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[58] D. Dwyre,et al. Hepatitis B, hepatitis C and HIV transfusion‐transmitted infections in the 21st century , 2011, Vox sanguinis.
[59] D. Pennell,et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload , 2011, Haematologica.
[60] Massimo Midiri,et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging , 2011, Haematologica.
[61] S. Manca-di-Villahermosa,et al. Iron-chelating therapy for transfusional iron overload. , 2011, The New England journal of medicine.
[62] Peter Hunold,et al. Magnetic resonance imaging in patients with a pacemaker system designed for the magnetic resonance environment. , 2011, Heart rhythm.
[63] D. Pennell,et al. A Decade Follow-up of a Thalassemia Major (TM) Cohort Monitored by Cardiac Magnetic Resonance Imaging (CMR): Significant Reduction In Patients with Cardiac Iron and In Total Mortality , 2010 .
[64] C. Stefanadis,et al. Ambulatory blood pressure profile in anemic hypertensive patients. , 2010, International journal of cardiology.
[65] G. Oudit,et al. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. , 2010, Journal of cardiac failure.
[66] G. Brittenham,et al. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. , 2010, Blood.
[67] T. Coates,et al. Follow‐up report on the 2‐year cardiac data from a deferasirox monotherapy trial , 2010, American journal of hematology.
[68] A. Chuansumrit,et al. High prevalence of "biochemical" adrenal insufficiency in thalassemics: is it a matter of different testings or decreased cortisol binding globulin? , 2010, The Journal of clinical endocrinology and metabolism.
[69] H. Tamary,et al. Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox. , 2010, Journal of pediatric hematology/oncology.
[70] G. Demirel,et al. THE ROLE OF Treg CELLS AND FoxP3 EXPRESSION IN IMMUNITY OF β-THALASSEMIA MAJOR AND β-THALASSEMIA TRAIT PATIENTS , 2010, Pediatric hematology and oncology.
[71] P. Cianciulli,et al. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. , 2010, Blood cells, molecules & diseases.
[72] E. Vichinsky,et al. Fertility potential in thalassemia major women: current findings and future diagnostic tools , 2010, Annals of the New York Academy of Sciences.
[73] Mark Fogel,et al. International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers , 2010, Journal of magnetic resonance imaging : JMRI.
[74] John C Wood,et al. Cardiovascular MRI in thalassemia major , 2010, Annals of the New York Academy of Sciences.
[75] F. Danjou,et al. Combined iron chelation therapy , 2010, Annals of the New York Academy of Sciences.
[76] C. Hershko. Pathogenesis and management of iron toxicity in thalassemia , 2010, Annals of the New York Academy of Sciences.
[77] J. Eccleston,et al. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. , 2010, Translational research : the journal of laboratory and clinical medicine.
[78] T. Coates,et al. Predicting pituitary iron and endocrine dysfunction , 2010, Annals of the New York Academy of Sciences.
[79] T. Coates,et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. , 2010, Blood.
[80] F. Valenza,et al. Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience , 2010, British journal of haematology.
[81] S. Wiangnon,et al. Retrospective Study on the Combination of Desferrioxamine and Deferasirox for Treatment of Iron-overloaded Thalassemic Patients: First Evidence of More Than 2 Years , 2010, Journal of pediatric hematology/oncology.
[82] D. Pennell,et al. Relation of myocardial T2* to right ventricular function in thalassaemia major. , 2010, European heart journal.
[83] M. Woodward,et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.
[84] Soso Fragatou,et al. Incidence of Hepatocellular Carcinoma in a Thalassemia Unit , 2010, Hemoglobin.
[85] Greg Brown,et al. Observational study of iron overload as assessed by magnetic resonance imaging in an adult population of transfusion‐dependent patients with β thalassaemia: significant association between low cardiac T2* < 10 ms and cardiac events , 2010, Internal medicine journal.
[86] Nancy M Albert,et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. , 2010, Journal of cardiac failure.
[87] Srirama V Swaminathan,et al. Separate MRI quantification of dispersed (ferritin‐like) and aggregated (hemosiderin‐like) storage iron , 2010, Magnetic resonance in medicine.
[88] M. Wright,et al. Controversies in cardiovascular medicine Drugs vs . ablation for the treatment of atrial fibrillation : the evidence supporting catheter ablation , 2010 .
[89] D. Pennell,et al. Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[90] M. Cappellini,et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias , 2010, Haematologica.
[91] D. Pennell,et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. , 2010, Blood.
[92] T. Coates,et al. Combining two orally active iron chelators for thalassemia , 2010, Annals of Hematology.
[93] F. Iellamo,et al. Testosterone Deficiency and Exercise Intolerance in Heart Failure: Treatment Implications , 2010, Current heart failure reports.
[94] G. Quarta,et al. Pregnancy and β-thalassemia: an Italian multicenter experience , 2010, Haematologica.
[95] D. Alehan,et al. The efficacy of tissue Doppler imaging in predicting myocardial iron load in patients with beta-thalassemia major: correlation with T2* cardiovascular magnetic resonance , 2010, The International Journal of Cardiovascular Imaging.
[96] G. Chouliaras,et al. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major , 2010, British journal of haematology.
[97] J. Kwiatkowski. Oral iron chelators. , 2010, Hematology/oncology clinics of North America.
[98] N. Papadopoulos,et al. Hyperchloremic Metabolic Acidosis Due to Deferasirox in a Patient with Beta Thalassemia Major , 2010, The Annals of pharmacotherapy.
[99] M. Cappellini,et al. The pituitary-adrenal axis in adult thalassaemic patients. , 2008, European journal of endocrinology.
[100] D. Tsiapras,et al. Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in beta-thalassemia major. , 2010, American heart journal.
[101] A. Kalogeropoulos,et al. Cardiac mortality in β‐thalassemia major: resting but not dobutamine stress echocardiography predicts mortality among initially cardiac disease‐free patients in a prospective 12‐year study , 2009, European journal of heart failure.
[102] J. Porter. Optimizing iron chelation strategies in beta-thalassaemia major. , 2009, Blood reviews.
[103] F. Warburton,et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone , 2009, Haematologica.
[104] G. Zanninelli,et al. Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients , 2009, British journal of haematology.
[105] J. Fernandes,et al. Early cardiac iron overload in children with transfusion-dependent anemias , 2009, Haematologica.
[106] T. Coates,et al. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. , 2009, Blood.
[107] R. Galanello,et al. Deferiprone Chelation Therapy for Thalassemia Major , 2009, Acta Haematologica.
[108] A. Taher,et al. Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major , 2009, Annals of Hematology.
[109] S. Ha,et al. Effects of Chelators (Deferoxamine, Deferiprone and Deferasirox) on the Growth of Klebsiella Pneumoniae and Aeromonas Hydrophila Isolated from Transfusion-Dependent Thalassemia Patients , 2009, Hemoglobin.
[110] S. Ha,et al. A Practical Chelation Protocol Based on Stratification of Thalassemic Patients by Serum Ferritin and Magnetic Resonance Imaging Cardiac T2* , 2009, Hemoglobin.
[111] F. Iellamo,et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. , 2009, Journal of the American College of Cardiology.
[112] G. Kolovou,et al. Effect of iron overload on exercise capacity in thalassemic patients with heart failure , 2009, The International Journal of Cardiovascular Imaging.
[113] Massimo Midiri,et al. Multislice multiecho T2* cardiac magnetic resonance for the detection of heterogeneous myocardial iron distribution in thalassaemia patients , 2009, NMR in biomedicine.
[114] I. Vasileiadis,et al. Impaired oxygen kinetics in beta‐thalassaemia major patients , 2009, Acta physiologica.
[115] J. Kline,et al. Effect of Glucose—Insulin—Potassium Infusion on Mortality in Critical Care Settings: A Systematic Review and Meta‐Analysis , 2009, Journal of clinical pharmacology.
[116] V. Positano,et al. Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major , 2009, Heart.
[117] D. Stakos,et al. Oxidised low‐density lipoprotein and arterial function in β‐thalassemia major , 2009, European journal of haematology.
[118] G. Neale,et al. Microarray analysis of liver gene expression in iron overloaded patients with sickle cell anemia and beta‐thalassemia , 2009, American journal of hematology.
[119] T. Coates,et al. Nutritional deficiencies in iron overloaded patients with hemoglobinopathies , 2009, American journal of hematology.
[120] D. Stakos,et al. Cardiovascular involvement in patients with beta-thalassemia major without cardiac iron overload. , 2009, International journal of cardiology.
[121] G. Forni,et al. The influence of treatment in specialized centers on survival of patients with thalassemia major , 2009, American journal of hematology.
[122] P. Cianciulli,et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. , 2009, Blood cells, molecules & diseases.
[123] Matthias Gutberlet,et al. Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper , 2009 .
[124] G. D’Amico,et al. Long‐term sequential deferiprone–deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial , 2009, British journal of haematology.
[125] N. Chattipakorn,et al. Iron overload thalassemic cardiomyopathy: iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity. , 2009, The Canadian journal of cardiology.
[126] Ali Taher,et al. Ventricular late potentials among thalassemia patients. , 2009, International journal of cardiology.
[127] A. Mancuso,et al. Electrocardiographic abnormalities in thalassemia patients with heart failure. , 2009, Cardiovascular & hematological disorders drug targets.
[128] E. Cassinerio,et al. Unexpected myocarditis in thalassaemia major patient screened for iron load cardiomyopathy , 2009, BMJ Case Reports.
[129] D J Pennell,et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major , 2009, Circulation.
[130] R. Bajoria,et al. Current Perspectives of Fertility and Pregnancy in Thalassemia , 2009, Hemoglobin.
[131] M. Cappellini,et al. High nontransferrin bound iron levels and heart disease in thalassemia major , 2009, American journal of hematology.
[132] M. Tsironi,et al. Heart Disease in Thalassemia Intermedia , 2009, Hemoglobin.
[133] D. Pennell,et al. T2* cardiovascular magnetic resonance in the management of thalassemia patients in Oman , 2009, Haematologica.
[134] P. Telfer. Update on Survival in Thalassemia Major , 2009, Hemoglobin.
[135] F. Flachskampf,et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. , 2008, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.
[136] I. Holm,et al. Bone Disease in Thalassemia: A Frequent and Still Unresolved Problem , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[137] I. Vasileiadis,et al. New insights into the exercise intolerance of β‐thalassemia major patients , 2008, Scandinavian journal of medicine & science in sports.
[138] William T. Abraham,et al. Focused Update : ACCF / AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults , 2013 .
[139] A. Inati,et al. Survival and Complications of Beta-Thalassemia in Lebanon , 2008, Acta Haematologica.
[140] T. Coates,et al. Longitudinal analysis of heart and liver iron in thalassemia major. , 2008, Blood.
[141] V. De Sanctis,et al. Mild subclinical hypothyroidism in thalassaemia major: prevalence, multigated radionuclide test, clinical and laboratory long-term follow-up study. , 2008, Pediatric endocrinology reviews : PER.
[142] V. De Sanctis,et al. Cardiomyopathy and pericardial effusion in a 7 year-old boy with beta-thalassaemia major, severe primary hypothyroidism and hypoparathyroidism due to iron overload. , 2008, Pediatric endocrinology reviews : PER.
[143] G. Brosnahan,et al. Acute interstitial nephritis due to deferasirox: a case report. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[144] Matthew W. Darlison,et al. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance , 2008, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[145] Michael Böhm,et al. Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.
[146] Emanuele Angelucci,et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias , 2008, Haematologica.
[147] Mark Doyle,et al. Routine evaluation of left ventricular diastolic function by cardiovascular magnetic resonance: A practical approach , 2008, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[148] E. Nagel,et al. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols , 2008, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[149] R. Galanello,et al. Glutathione S‐transferase gene polymorphism and cardiac iron overload in thalassaemia major , 2008, British journal of haematology.
[150] A. Koren,et al. Renal function in children with β-thalassemia major and thalassemia intermedia , 2008, Pediatric Nephrology.
[151] A. Kalogeropoulos,et al. Global vasomotor dysfunction and accelerated vascular aging in beta-thalassemia major. , 2008, Atherosclerosis.
[152] H. Kulkarni,et al. Influence of iron chelators on myocardial iron and cardiac function in transfusion‐dependent thalassaemia: a systematic review and meta‐analysis , 2008, British journal of haematology.
[153] T. Coates,et al. Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major , 2008, British journal of haematology.
[154] S. Ha,et al. Effect of deferasirox (ICL670) on arterial function in patients with beta‐thalassaemia major , 2008, British journal of haematology.
[155] T. Coates,et al. Onset of cardiac iron loading in pediatric patients with thalassemia major , 2008, Haematologica.
[156] P. Cianciulli,et al. Guideline recommendations for heart complications in thalassemia major , 2008, Journal of cardiovascular medicine.
[157] W. Au,et al. A cross-sectional magnetic resonance imaging assessment of organ specific hemosiderosis in 180 thalassemia major patients in Hong Kong , 2008, Haematologica.
[158] V. De Sanctis,et al. A rare cause of heart failure in iron-overload thalassaemic patients-primary hypoparathyroidism. , 2008, Georgian medical news.
[159] K. Ho. Intravenous magnesium for cardiac arrhythmias: jack of all trades. , 2008, Magnesium research.
[160] D. Pennell,et al. Journal of Cardiovascular Magnetic Resonance Open Access Combined Chelation Therapy in Thalassemia Major for the Treatment of Severe Myocardial Siderosis with Left Ventricular Dysfunction , 2008 .
[161] T. Coates,et al. Atrial dysfunction as a marker of iron cardiotoxicity in thalassemia major , 2008, Haematologica.
[162] V. Positano,et al. Standardized T2* Map of a Normal Human Heart to Correct T2* Segmental Artefacts; Myocardial Iron Overload and Fibrosis in Thalassemia Intermedia Versus Thalassemia Major Patients and Electrocardiogram Changes in Thalassemia Major Patients , 2008, Hemoglobin.
[163] M. Tsironi,et al. Congestive Heart Failure and Treatment in Thalassemia Major , 2008, Hemoglobin.
[164] M. Tsironi,et al. The heart in transfusion dependent homozygous thalassaemia today – prediction, prevention and management , 2007, European journal of haematology.
[165] M. Cappellini,et al. Guidelines for the Clinical Management of Thalassaemia , 2008 .
[166] U. Kukongviriyapan,et al. Endothelial dysfunction and oxidant status in pediatric patients with hemoglobin E-beta thalassemia. , 2008, Pediatric cardiology.
[167] R. McKelvie,et al. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. , 2008, The Canadian journal of cardiology.
[168] M. Gharagozloo,et al. Double-faced cell-mediated immunity in β-thalassemia major: stimulated phenotype versus suppressed activity , 2008, Annals of Hematology.
[169] J. Kelton,et al. Current options for the treatment of idiopathic thrombocytopenic purpura. , 2007, Seminars in hematology.
[170] K. Ataga,et al. β‐Thalassaemia and sickle cell anaemia as paradigms of hypercoagulability , 2007, British journal of haematology.
[171] F. R. Ghader,et al. High-dose deferoxamine treatment (intravenous) for thalassaemia patients with cardiac complications. , 2007, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.
[172] A. Hamdy,et al. Right Ventricular Function in Patients with Beta Thalassemia: Relation to Serum Ferritin Level , 2007, Echocardiography.
[173] A. Maggio. Light and shadows in the iron chelation treatment of haematological diseases , 2007, British journal of haematology.
[174] E. Gotsis,et al. Comparison of echocardiographic (US) volumetry with cardiac magnetic resonance (CMR) imaging in transfusion dependent thalassemia major (TM) , 2007, Cardiovascular ultrasound.
[175] D. Pennell,et al. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron , 2007, Journal of magnetic resonance imaging : JMRI.
[176] D. Pennell,et al. Black‐blood T2* technique for myocardial iron measurement in thalassemia , 2007, Journal of magnetic resonance imaging : JMRI.
[177] D. Kremastinos. Heart failure in beta-thalassaemia: a local or universal health problem? , 2007, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.
[178] T. Ganz,et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. , 2007, Haematologica.
[179] K. Ho,et al. Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis , 2007, Heart.
[180] D. Pennell,et al. A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance , 2007, Circulation.
[181] H. Nick. Deferasirox (Exjade ® , ICL670) Preclinical Overview , 2007 .
[182] M. Hentze,et al. Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1 , 2007, Nature Medicine.
[183] R. Galanello,et al. Effects of combined deferiprone and desferrioxamine iron chelating therapy in β‐thalassemia major end‐stage heart failure , 2007 .
[184] P. Storey,et al. R2* imaging of transfusional iron burden at 3T and comparison with 1.5T , 2007, Journal of magnetic resonance imaging : JMRI.
[185] M. Guglin,et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.
[186] E. Noulsri,et al. Activated platelet‐derived microparticles in thalassaemia , 2007, British journal of haematology.
[187] C. Borgna-Pignatti. SURVIVING WITH THALASSEMIA MAJOR: The Italian Experience , 2007, Pediatric hematology and oncology.
[188] R. Galanello,et al. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report. , 2007, European journal of heart failure.
[189] V. Laosombat,et al. A Low Dose Adrenocorticotropin Test (1 μg ACTH) for the Evaluation of Adrenal Function in Children with ß-Thalassemia Receiving Hypertransfusion with Suboptimal Iron-chelating Therapy , 2007, Journal of pediatric endocrinology & metabolism : JPEM.
[190] E. Gotsis,et al. Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. , 2007, Haematologica.
[191] U. Kukongviriyapan,et al. Endothelial Dysfunction and Oxidant Status in Pediatric Patients with Hemoglobin E-β Thalassemia , 2007, Pediatric Cardiology.
[192] M. Cappellini,et al. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). , 2007, Blood.
[193] S. Ha,et al. Carotid intima‐media thickness is increased and related to arterial stiffening in patients with beta‐thalassaemia major , 2006, British journal of haematology.
[194] Dudley J Pennell,et al. Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. , 2006, European heart journal.
[195] F. Melis,et al. Exercise capacity and cardiovascular changes in patients with β‐thalassaemia major , 2006 .
[196] A. Taher,et al. Effect of L-carnitine on the physical fitness of thalassemic patients , 2006, Annals of Hematology.
[197] T. Coates,et al. MRI detects myocardial iron in the human heart , 2006, Magnetic resonance in medicine.
[198] G. Giannakoulas,et al. Survival in thalassaemia major patients. , 2006, Circulation journal : official journal of the Japanese Circulation Society.
[199] G. Giannakoulas,et al. Survival in Thalassaemia Major Patients : Prognostic Value of Doppler-Demonstrated Left Ventricular Restrictive Filling Pattern , 2006 .
[200] A. Inati,et al. Pregnancy in patients with β‐thalassemia intermedia: Outcome of mothers and newborns , 2006 .
[201] G. Rahav,et al. Severe infections in thalassaemic patients: prevalence and predisposing factors , 2006, British journal of haematology.
[202] Mark A Westwood,et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. , 2006, Blood.
[203] V. Positano,et al. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload , 2006, Journal of magnetic resonance imaging : JMRI.
[204] M. Tsironi,et al. Hypocalcemic Heart Failure in Thalassemic Patients , 2006, International journal of hematology.
[205] S. Perrotta,et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. , 2006, Blood.
[206] A. Cnaan,et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. , 2006, Blood.
[207] V. Positano,et al. Evaluation of the efficacy of oral deferiprone in β‐thalassemia major by multislice multiecho T2* , 2006, European journal of haematology.
[208] Jan-Gowth Chang,et al. Glutathione S-Transferase M1 Gene Polymorphisms are Associated with Cardiac Iron Deposition in Patients with β-Thalassemia Major , 2006 .
[209] T. Coates,et al. Improved R2* measurements in myocardial iron overload , 2006, Journal of magnetic resonance imaging : JMRI.
[210] A. Mancuso,et al. A Prospective Study of Hepatocellular Carcinoma Incidence in Thalassemia , 2006, Hemoglobin.
[211] D. Pennell,et al. Development of Thalassaemic Iron Overload Cardiomyopathy despite Low Liver Iron Levels and Meticulous Compliance to Desferrioxamine , 2006, Acta Haematologica.
[212] S. Ansari,et al. PREGNANCY IN PATIENTS TREATED FOR BETA THALASSEMIA MAJOR IN TWO CENTERS (ALI ASGHAR CHILDREN'S HOSPITAL AND THALASSEMIA CLINIC): Outcome for Mothers and Newborn Infants , 2006, Pediatric hematology and oncology.
[213] A. Inati,et al. Pregnancy in patients with beta-thalassemia intermedia: outcome of mothers and newborns. , 2004, American journal of hematology.
[214] S. Tsai,et al. Lipid peroxidation and antioxidative status in β-thalassemia major patients with or without hepatitis C virus infection , 2006 .
[215] Jan-Gowth Chang,et al. Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major. , 2006, Hemoglobin.
[216] M. Felisi,et al. Risk factors for death in patients with beta-thalassemia major: results of a case-control study. , 2006, Haematologica.
[217] S. Tsai,et al. Lipid peroxidation and antioxidative status in beta-thalassemia major patients with or without hepatitis C virus infection. , 2006, Clinical chemistry and laboratory medicine.
[218] F. Melis,et al. Exercise capacity and cardiovascular changes in patients with beta-thalassaemia major. , 2006, Clinical physiology and functional imaging.
[219] M. Angastiniotis,et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. , 2006, Haematologica.
[220] A. Vincenzi,et al. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone. , 2006, Haematologica.
[221] D. Pennell,et al. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. , 2006, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[222] D. Pennell,et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. , 2006, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[223] V. Santinelli,et al. Atrial fibrillation ablation: state of the art. , 2005, The American journal of cardiology.
[224] R. Moats,et al. Physiology and Pathophysiology of Iron Cardiomyopathy in Thalassemia , 2005, Annals of the New York Academy of Sciences.
[225] E. Kanavakis,et al. Longitudinal Study of Survival and Causes of Death in Patients with Thalassemia Major in Greece , 2005, Annals of the New York Academy of Sciences.
[226] David N. Firmin,et al. Intercentre Reproducibility of Magnetic Resonance T2* Measurements of Myocardial Iron in Thalassaemia , 2005, The International Journal of Cardiovascular Imaging.
[227] J. Ornato,et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .
[228] N. Gourtsoyiannis,et al. Adrenal glands in beta-thalassemia major: magnetic resonance (MR) imaging features and correlation with iron stores , 2005, European Radiology.
[229] D. Pennell,et al. Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major , 2005, Journal of magnetic resonance imaging : JMRI.
[230] Thomas D. Coates,et al. Cardiac Iron Determines Cardiac T2*, T2, and T1 in the Gerbil Model of Iron Cardiomyopathy , 2005, Circulation.
[231] S. Ha,et al. Ventriculo-vascular interactions in patients with β thalassaemia major , 2005, Heart.
[232] A. Geha,et al. Cardiac transplantation in patients with iron overload cardiomyopathy. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[233] H. Iwao,et al. Core Protein of Hepatitis C Virus Induces Cardiomyopathy , 2005, Circulation research.
[234] M. Tsironi,et al. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report , 2005, European journal of haematology.
[235] I. Tsatra,et al. Prevalence and severity of liver disease in patients with b thalassemia major. A single-institution fifteen-year experience. , 2005, Haematologica.
[236] A. Srivatsa,et al. Assessment of adrenal endocrine function in Asian thalassemics. , 2005, Indian pediatrics.
[237] S. Ha,et al. Ventriculo-vascular interactions in patients with beta thalassaemia major. , 2005, Heart.
[238] M. Tsironi,et al. Hypoparathyroidism and heart failure in thalassemic patients: a case report. , 2004, Pediatric endocrinology reviews : PER.
[239] J. Towbin,et al. International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[240] D. Farmakis,et al. Cardiac status in well‐treated patients with thalassemia major , 2004, European journal of haematology.
[241] D. Pennell,et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance , 2004, British journal of haematology.
[242] P. Jarritt,et al. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. , 2004, Blood.
[243] E. Neufeld,et al. Complications of beta-thalassemia major in North America. , 2004, Blood.
[244] A. Taher,et al. Improvement of Cardiac Function in Thalassemia major Treated with L-Carnitine , 2004, Acta Haematologica.
[245] Marvin D Nelson,et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. , 2004, Blood.
[246] James C Moon,et al. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. , 2004, American heart journal.
[247] M. Cappellini,et al. Hepatocellular carcinoma in the thalassaemia syndromes , 2004, British journal of haematology.
[248] A. Cnaan,et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.
[249] C. Peng,et al. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with β-thalassemia major , 2004, Annals of Hematology.
[250] S. Laradi,et al. Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. , 2003, Clinica chimica acta; international journal of clinical chemistry.
[251] Mark A Westwood,et al. Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia , 2003, Journal of magnetic resonance imaging : JMRI.
[252] G. Forni,et al. Typical manifestation of acute congestive heart failure in patients with Thalassaemia major causing diagnostic delay in the emergency room , 2003, European journal of heart failure.
[253] Sheryl E. Koch,et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy , 2003, Nature Medicine.
[254] D. Pennell,et al. A single breath‐hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload , 2003, Journal of magnetic resonance imaging : JMRI.
[255] G. Bosi,et al. Left ventricular remodelling, and systolic and diastolic function in young adults with β thalassaemia major: a Doppler echocardiographic assessment and correlation with haematological data , 2003, Heart.
[256] H. Tamary,et al. Reversal of cardiac complications in thalassemia major by long‐term intermittent daily intensive iron chelation , 2003, European journal of haematology.
[257] H. Eiskjaer,et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. , 2003, Blood.
[258] R. Hider,et al. Emerging understanding of the advantage of small molecules such as hydroxypyridinones in the treatment of iron overload. , 2003, Current medicinal chemistry.
[259] Y. Liu,et al. Differential accumulation of non-transferrin-bound iron by cardiac myocytes and fibroblasts. , 2003, Journal of molecular and cellular cardiology.
[260] A. Hoffbrand,et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients , 2003, British journal of haematology.
[261] I. Papassotiriou,et al. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. , 2003, Haematologica.
[262] A. Piga,et al. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. , 2003, Haematologica.
[263] F. Jensen,et al. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. , 2003, Blood.
[264] D. Pennell,et al. Tissue Doppler echocardiography in patients with thalassaemia detects early myocardial dysfunction related to myocardial iron overload. , 2003, European heart journal.
[265] Y. Cheung,et al. Arterial Stiffness and Endothelial Function in Patients With &bgr;-Thalassemia Major , 2002, Circulation.
[266] D. Pennell,et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia , 2002, The Lancet.
[267] W. Braselton,et al. Earliest cardiac toxicity induced by iron overload selectively inhibits electrical conduction. , 2002, Journal of applied physiology.
[268] D. Pennell,et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. , 2002, The American journal of cardiology.
[269] A. Nicolucci,et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. , 2002, Blood.
[270] J. Porter,et al. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. , 2002, Best practice & research. Clinical haematology.
[271] J. Eaton,et al. Molecular bases of cellular iron toxicity. , 2002, Free radical biology & medicine.
[272] C. Hidalgo,et al. Redox regulation of calcium release in skeletal and cardiac muscle. , 2002, Biological research.
[273] D N Firmin,et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.
[274] D. Tsiapras,et al. Heart failure in beta thalassemia: a 5-year follow-up study. , 2001, The American journal of medicine.
[275] G. Link,et al. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. , 2001, The Journal of laboratory and clinical medicine.
[276] D. Farmakis,et al. Cardiac involvement in thalassemia intermedia: a multicenter study. , 2001, Blood.
[277] W. Bartfay,et al. Selenium and Glutathione Peroxidase With Beta-Thalassemia Major , 2001, Nursing research.
[278] A. Anarat,et al. Renal function in pediatric patients with β-thalassemia major , 2000, Pediatric Nephrology.
[279] E. Prystowsky,et al. Management of malignant ventricular arrhythmias and cardiac arrest , 2000, Critical care medicine.
[280] A. Hoffbrand,et al. Hepatic iron concentration combined with long‐term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major , 2000, British journal of haematology.
[281] C. McLaren,et al. Hepatic iron concentration and total body iron stores in thalassemia major. , 2000, The New England journal of medicine.
[282] D J Pennell,et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? , 2000, European heart journal.
[283] Matthew Darlison,et al. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register , 2000, The Lancet.
[284] J. Porter,et al. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia , 2000 .
[285] A. Anarat,et al. Renal function in pediatric patients with beta-thalassemia major. , 2000, Pediatric nephrology.
[286] S. Banani,et al. Cortisol and adrenocorticotropic hormone response to surgical stress (splenectomy) in thalassemic patients , 2000, Pediatric Surgery International.
[287] M. Shimada,et al. High Prevalence of Wolbachia in the Azuki Bean Beetle Callosobruchus chinensis (Coleoptera, Bruchidae) , 1999 .
[288] J. Maclouf,et al. A chronic hypercoagulable state in patients with β‐thalassaemia major is already present in childhood , 1999, British journal of haematology.
[289] D. Tsiapras,et al. Association of heart failure in homozygous beta-thalassemia with the major histocompatibility complex. , 1999, Circulation.
[290] Y. Kuryshev,et al. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Implications for the arrhythmogenesis of human siderotic heart disease. , 1999, Circulation.
[291] S. Mariotti,et al. High prevalence of thyroid dysfunction in adult patients with β-thalassemia major submitted to amiodarone treatment , 1999, Journal of endocrinological investigation.
[292] C. Stefanadis,et al. Exercise capacity in patients with beta-thalassemia major: relation to left ventricular and atrial size and function. , 1998, American heart journal.
[293] N. Olivieri,et al. Infection due to Yersinia enterocolitica in a series of patients with beta-thalassemia: incidence and predisposing factors. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[294] Wright,et al. Combined therapy with deferiprone and desferrioxamine , 1998, British journal of haematology.
[295] M. Cappellini,et al. Survival and Disease Complications in Thalassemia Major , 1998, Annals of the New York Academy of Sciences.
[296] M. Jessup,et al. Diagnosis and Management of Iron‐induced Heart Disease in Cooley's Anemia , 1998, Annals of the New York Academy of Sciences.
[297] P. Malasit,et al. Renal tubular function in β-thalassemia , 1998, Pediatric Nephrology.
[298] F. Veglio,et al. Blood pressure and heart rate in young thalassemia major patients. , 1998, American Journal of Hypertension.
[299] M. Angastiniotis,et al. Fertility in female patients with thalassemia. , 1998, Journal of pediatric endocrinology & metabolism : JPEM.
[300] P. Malasit,et al. Renal tubular function in beta-thalassemia. , 1998, Pediatric nephrology.
[301] A. Yardumian,et al. Pregnancy management and outcomes in women with thalassaemia major. , 1998, Journal of pediatric endocrinology & metabolism : JPEM.
[302] G. Tenderich,et al. Heart transplantation for end‐stage heart failure caused by iron overload , 1997, British journal of haematology.
[303] Sudhir V. Shah,et al. Oxidant mechanisms in toxic acute renal failure. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[304] L. Tesoriere,et al. Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. , 1996, Blood.
[305] R. Abeysinghe,et al. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. , 1996, Blood.
[306] V. Frontini,et al. High‐dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration , 1996, American journal of hematology.
[307] A. Piga,et al. Results of long-term iron-chelating therapy. , 1996, Acta haematologica.
[308] A. Hoffbrand,et al. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload , 1995, British journal of haematology.
[309] P. Toutouzas,et al. Myocarditis in β-Thalassemia Major A Cause of Heart Failure , 1995 .
[310] I. Pessah,et al. Iron(II) is a modulator of ryanodine-sensitive calcium channels of cardiac muscle sarcoplasmic reticulum. , 1995, Toxicology and applied pharmacology.
[311] P. Toutouzas,et al. Myocarditis in beta-thalassemia major. A cause of heart failure. , 1995, Circulation.
[312] J. H. MacMillan,et al. Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .
[313] C. McLaren,et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. , 1994, The New England journal of medicine.
[314] G. Papa,et al. Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy. , 1994, Kidney international.
[315] C. Hershko,et al. Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells. , 1994, Blood.
[316] D. Templeton,et al. Brief report: combined liver and heart transplantation for end-stage iron-induced organ failure in an adult with homozygous beta-thalassemia. , 1994, The New England journal of medicine.
[317] C. Savona-Ventura,et al. Beta-thalassemia syndromes and pregnancy. , 1994, Obstetrical & gynecological survey.
[318] J. H. MacMillan,et al. Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.
[319] R. Abeysinghe,et al. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. , 1993, Drug metabolism and disposition: the biological fate of chemicals.
[320] G. Papa,et al. Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis. , 1992, Haematologica.
[321] G. Michel,et al. FIRST REPORT OF A CARDIAC TRANSPLANTATION IN A PATIENT WITH THALASSAEMIA MAJOR , 1991, British journal of haematology.
[322] K. Ehlers,et al. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. , 1991, The Journal of pediatrics.
[323] M. Freedman,et al. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. , 1990, American journal of diseases of children.
[324] G. Schilirò,et al. Acute changes in renal function associated with deferoxamine therapy. , 1990, American journal of diseases of children.
[325] A. Piga,et al. SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJOR , 1989, The Lancet.
[326] W. Taylor,et al. Determination of Iron in Cardiac and Liver Tissues by Plasma Emission Spectroscopy , 1987, Annals of clinical biochemistry.
[327] M. Athanasiou-Metaxa,et al. Iron-related disturbances of cell-mediated immunity in multitransfused children with thalassemia major. , 1987, Clinical and experimental immunology.
[328] E. Chew,et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. , 1986, The New England journal of medicine.
[329] C. Hershko,et al. Heart cells in culture: a model of myocardial iron overload and chelation. , 1985, The Journal of laboratory and clinical medicine.
[330] R. Peto,et al. Survival and desferrioxamine in thalassaemia major. , 1982, British medical journal.
[331] B. Modell. The management of the improved prognosis in thalassemia major. , 1982, Birth defects original article series.
[332] R. Winkle,et al. Myocardial involvement in idiopathic hemochromatosis. Morphologic and clinical improvement following venesection. , 1981, American Journal of Medicine.
[333] D. Fitchett,et al. Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. , 1980, Cardiovascular research.
[334] K. Ehlers,et al. LONGITUDINAL STUDY OF CARDIAC FUNCTION IN THALASSEMIA MAJOR * , 1980, Annals of the New York Academy of Sciences.
[335] A. Nienhuis,et al. Detection of early cardiac dysfunction in patients with severe beta-thalassemia and chronic iron overload. , 1979, The New England journal of medicine.
[336] S. Kaye,et al. Cardiac arrhythmias in thalassaemia major: evaluation of chelation treatment using ambulatory monitoring. , 1978, British medical journal.
[337] K. Spyroglou,et al. Effect of blood transfusion on the immune response of children with thalassaemia. , 1977, Acta haematologica.
[338] W. Roberts,et al. Iron in the heart. Etiology and clinical significance. , 1971, The American journal of medicine.
[339] P. Schellhammer,et al. Histochemical Studies of the Myocardium and Conduction System in Acquired Iron‐Storage Disease , 1967, Circulation.
[340] M. A. Engle,et al. Late Cardiac Complications of Chronic, Severe, Refractory Anemia with Hemochromatosis , 1964, Circulation.
[341] M. A. Engle. Cardiac Involvement in Cooley's Anemia , 1964, Annals of the New York Academy of Sciences.